Mikhail Blagosklonny is a Scientist in Oncology and focuses on cancer and aging. Blagosklonny is based at Roswell Park Cancer Institute, and his research features Biogerontology, the study on aging mechanisms, the prevalence of diseases among aged people, effective anti-aging drugs and likable therapies that enhance the quality of healthy body cells and the way to eliminate cell damage.
Blagosklonny pursued his MD in internal medicine at First Pavlov State Medical University, St. Petersburg. He went on to study a Ph.D. in Experimental Medicine & Cardiology in the same school. Following his studies, Blagosklonny became an associate professor at the New York Medical College before later joining Ordway Research Institute as the Senior Scientist. Blagosklonny is currently one of the best-known cancer researchers with a broad and wealth of experience in the sector. Visit ResearchGate.Net to know more about Mikhail’s latest work.
Through his contribution into Oncortarget, Mikhail Blagosklonny gives insight in the way rejuvenation of body cells assists in minimizing the prevalence of cancer between the aged. Blagosklonny goes further to elaborate how aging is caused by continued damaging of molecules by offering the TOR signaling likable hypothesis that defines the association between the aging and cancer. From such findings, Blagosklonny proposes utilization of Rapamycin, the conventional cancer treatment drug. He also terms aging as the progressive of growth of body cells.
According to Blagosklonny, by using Rapamycin, it is possible to minimize the aging impact on humans as the drug increases immunity in the body. Over the years, researchers have provided different results on the utilization of anti-aging outcomes in cancer management. Results from study volunteers portrayed distinctive outcomes in different people. However, with the usage of several newfound models, application of anti-aging drugs has been proved to be an effectual way of increasing immunity in the body.
Blagosklonny trusts in the possibility of controlling cancer and aging and further believes the method provides an effective treatment of cancer by using Rapamycin, which is an anti-aging drug. He has been categorized as among the most enthusiastic supporters of Rapaycin in a long-term study with his research ranging touching on different areas such as cellular & molecular biology and clinical investigations among others. It mainly entails tumor suppressors, ontogenesis, signal transduction, apoptosis, mitosis, anticancer therapeutics, and drug resistance for normal cells selective protection.
Blagosklonny is the author of aging hyperfunction hypothesis. He has written on chemotherapeutic and cyclotherapy engineering and recognized for his keen interest in oncology. Blagosklonny believes that controlling aging and cancer is possible and has the trust that cancer can be cured and that is the reason he proposed utilization of Rapamycin. He has more than 300 research articles, reviews, and book chapters that are published under his name. Blagosklonny commitments and efforts have contributed to making him part of the leading Oncology researchers around the globe.